Kornimate/medical-research-clean huggingface dataset:
the effect of using a kaleidoscope on fear and pain in children

Conditions: Fracture; Complication Orthopedic Procedure

Summary: the research was conducted in randomized controlled experimental type between may 2022 and december2023. the universe of the research consisted of children and their parents who were diagnosed with a fracture, applied to the orthopedic outpatient clinic and emergency department of the erzurum ataturk university health research and application center and referred to the orthopedic clinic, and decided to undergo a cast procedure for treatment. the sample of the research consisted of a total of 70 children and their parents, including 35 control groups and 35 kaleidoscope groups, who met the research criteria from this universe. the children in the kaleidoscope group were shown the kaleidoscope. no intervention other than routine application was applied to the control group. "introductory information form", "wong-baker facial expressions rating scale and child fear scale were used in the collection of data.

type of study: the study was designed as a randomized controlled experimental study. place and time of research: the research was conducted between march 2022 and december 2023 as a randomized controlled experimental study. the study population consisted of patients who sought treatment at the orthopedics polyclinic and emergency department of erzurum atatürk university health research and application center. these patients were referred to the orthopedics clinic and diagnosed with fractures, such as humerus, wrist, finger, tibia, femur, and ankle fractures, for which plastering was performed as treatment. specifically, the study included children aged 6 to 12 years. the sample size for the study was determined through a power analysis and ultimately consisted of a total of 70 children, with 35 children assigned to both the control group and the kaleidoscope group. the children in the kaleidoscope group were exposed to a kaleidoscope, while the control group received no intervention beyond routine medical practice. to collect data, the researchers utilized an "introductory information form," the "wong-baker faces pain rating scale," and the "children fear scale." the data were analyzed using percentage distributions, mean, standard deviation, chi-square test, and independent groups t-test. throughout the research, ethical principles were strictly followed.

Eligibility criteria:
inclusion criteria: * being a child in the 6-12 age group, * the child's willingness to participate in the study, * the parent's volunteering to participate in the study, * absence of intellectual disability of the child and parent, * the child and the parent speak turkish and are open to communication. exclusion criteria: * the child has a chronic disease that can cause pain, * the child has used analgesics within 24 hours before admission to the hospital, * the child has visual impairment.
reducing cognitive impairment by management of heart failure as a modifiable risk factor

Conditions: Heart Failure; Cognitive Impairment; Dementia; Left Ventricular Dysfunction; Cognitive Change; Cognitive Decline

Summary: this study will test the feasibility and effectiveness of an innovative model of care for cognitively impaired patients with heart failure. this program aims to improve cognition, reduce dementia risk and cardiovascular events, and will be supported by innovative digital technology for wide scale rollout and implementation. findings from this research will transform the way healthcare is delivered to cognitively impaired patients with heart disease who have a very high risk of developing dementia.


Eligibility criteria:
inclusion criteria: 1. hospitalised with hf as primary or secondary diagnosis. 2. at least mild cognitive impairment (ci) based on montreal cognitive assessment (moca) on hospital discharge. exclusion criteria: 1. unable to provide written consent; requiring palliative care; or participating in another rct 2. recovery of cognitive function shortly after hospital discharge: to ensure that we only include patients with "true" ci, any patients with a repeated moca\>25 at 2 weeks post-discharge will be excluded. 3. terminal illness (eg. cancer) that may influence 12-month prognosis.
non-interventional study to establish consensus on management of metastatic hormone-sensitive prostate cancer patients

Conditions: Metastatic Hormone-Sensitive Prostate Cancer

Summary: the purpose of this study is to establish an expert consensus recommendations on managing patients with mhspc in south korea, and to provide clinicians with a comprehensive guide to support their clinical decision making. there are no secondary objectives for this study.

data collection for this study will be conducted through 2 rounds of web-based surveys of health care professionals (hcps). a meeting with the panelists will be held as a 3rd round if a consensus for pre determined key questions is not achieved after the 2 rounds of the survey.

Eligibility criteria:
inclusion criteria: * urologist from university hospitals in south korea. * has a minimum 10 years of practice experience (experience as a military or public health doctor could be considered practice experience) * sees a minimum of 50 mhspc patients in a year. * at least 10 publications in scie (science citation index expanded) journals in the past 5 years. exclusion criteria: * urologist in private practice.

Keywords: mhspc urological cancers
electroporation for cancer treatment real world registry

Conditions: Skin Cancer; Gastrointestinal Cancer

Summary: this registry aims to assess real-world long-term disease outcomes for patients treated using reversible electroporation and a chemotherapeutic or calcium; in particular tumour response rates and recurrence rates. the study also aims to characterise side effects and the occurrence of adverse events and their relationship to the treatment.


Eligibility criteria:
inclusion criteria: * any patient who has been treated using calcium electroporation * any patient who has been treated using electrochemotherapy * patients must be mentally capable of understanding the information given * patients must give written informed consent. exclusion criteria: * none

Keywords: pulsed electric fields reversible electroporation electrochemotherapy ca-electroporation
magnetic resonance imaging of breast cancer

Conditions: Breast Cancer; Breast Cancer Non-invasive Breast Cancer

Summary: to compare magnetic resonance imaging (mri) with more well established diagnostic imaging techniques to determine which method best finds and defines breast cancer.


Eligibility criteria:
inclusion criteria * female * documented breast physical examination, * documented mammography within 3 months of the mr studies * palpable or mammographically-detected suspect breast lesions * women who have already undergone lumpectomy for breast cancer and have post-biopsy/post-radiation changes will be eligible if they have mammographically-detected or palpable breast abnormalities which are sufficiently suspicious to merit core needle or surgical biopsy. exclusion criteria: * male by birth * able to complete the mr examination. subjects will be interviewed by one of the investigators for the usual contraindications to * mr contraindications including * pacemakers * metallic implants * severe claustrophobia * aneurysm clips * pregnancy * current lactation * other conditions precluding proximity to a strong magnetic field. * received an enhanced mr procedure within 48 hours, * iodinated contrast within six hours, * known sensitivity to mr contrast agents, * not likely to complete the study in full or * other clinical reason which would preclude participation in the protocol.
observation of imageready™ mr conditional pacing system in china

Conditions: Arhythmia; Atrioventricular Heart-block; Chronic Bundle Branch or Branch Block; Carotid Sinus Hypersensitivity Reaction Syndrome; Vasovagal Syncope

Summary: to observe the safety and efficacy of imageready™ mr conditional pacing system in chinese subjects

key inclusion criteria: 1. subject must have the image ready system as their initial (de novo) pacing system implant. 2. subject has a class i or ii indication for implantation of a pacemaker according to the cspe guidelines. 3. subject is able and willing to undergo an mr scan.• 4. subject is willing and capable of providing informed consent and participating in all testing/ visits associated with this clinical study at the intervals defined by this protocol. 5. subject is age 18 or above. key exclusion criteria 1. subject has or has had any pacing or icd system implants. 2. subject has any implants or devices that are not suitable for mr scan. 3. subject is enrolled in any other concurrent study that might interfere with this study. 4. subject has documented life expectancy of less than 12 months. 5. women of childbearing potential who are or might be pregnant at the time of this study. primary safety endpoint: mr scan related complication free rate analyzed at mri visit +1 month. primary efficacy endpoint: 1. pacing threshold (at 0.5 ms pulse width) comparison pre and 1 month post mr scan: pacing threshold increase ≤ 0.5 v after scan. 2. sensed amplitude comparison pre- and 1 month post-mr scan: sensed amplitude: ≥ 1.0 mv after scan, and ≥ 50% of that before scan.

Eligibility criteria:
inclusion criteria: * subject must have the imageready system as their initial (de novo) pacing system implant * subject has a class i or ii indication for implantation of a pacemaker according to the cspe guidelines5 * subject is able and willing to undergo an mr scan * subject is willing and capable of providing informed consent and participating in all testing/ visits associated with this clinical study at the intervals defined by this protocol * subject is age 18 or above exclusion criteria: * subject has or has had any pacing or icd system implants * subject has any implants or devices that are not suitable for mr scan * subject is enrolled in any other concurrent study that might interfere with this study * subject has documented life expectancy of less than 12 months * women of childbearing potential who are or might be pregnant at the time of this study
10 year coronary heart disease (chd) risk evaluation and its treatment pattern analysis in postmenopausal early breast cancer (ebc) patients taking aromatase inhibitors (ai)

Conditions: Breast Cancer

Summary: 10-year chd risk evaluation and its treatment pattern analysis in postmenopausal early breast cancer patients taking aromatase inhibitors.


Eligibility criteria:
inclusion criteria: * early breast cancer patients * postmenopausal status * patients taking aromatase inhibitor as adjuvant treatment no longer than 6 months exclusion criteria: * advanced breast cancer patients(stage iii, iv) * patients who are hard to be analysed by limitation of chart record according to investigators discretion * patients who already have been registered in this study

Keywords: chd-risk breast cancer aromatase inhibitors postmenopausal early breast cancer
a pilot study to investigate the safety and immunologic activity ags-004 an autologous hiv immunotherapeutic agent.

Conditions: HIV Seropositivity; Acquired Immunodeficiency Syndrome

Summary: to investigate the safety and immunologic activity of ags-004, an autologous hiv immunotherapeutic, in hiv-infected adults currently on stable antiretroviral therapy (art) with durable viral suppression.

although an hiv infection can induce weak immune responses, current hiv immunotherapy using consensus antigens has not shown consistent clinical activity. the absence of clinical activity is associated with an inability to raise cytotoxic t lymphocytes (ctl) against hiv antigens and a failure to induce t cell memory. while strong immune responses may be generated to a consensus antigen, those responses do not offer antiviral protection against a patient's individual viral burden. the infecting virus' antigen variability likely prevents the establishment of effective cd4+ t cell memory and a strong cd8+ t cell effector arm. we are investigating the induction of ctl responses in hiv-infected subjects by a novel hiv immunotherapeutic agent (ags-004) in an effort to overcome the lack of polyvalent specificity of the immune response for autologous hiv antigens which has been one of the primary reasons for the failure of hiv immunotherapy to date. this pilot study will investigate the safety and immunologic activity of ags-004 an autologous hiv immunotherapeutic agent.

Eligibility criteria:
inclusion criteria: * men or women age 18 years and over, * documented hiv-1 infection, * durable viral suppression (≤ 200 copies hiv-1 rna / ml) on first art regimen for at least 12 weeks prior to entry, * availability of ≥ 2.5ml of continually-frozen plasma before starting art (≥30,000 copies/ml), * cd4+ t cell count ≥200 cells/mm3 at time of pre-art sample, * cd4+ t cell count of ≥350 cells/mm3 obtained within 4 weeks of study entry, exclusion criteria: * no co-infection with hbv or hcv, * no history of lymph node irradiation or dissection, * no prior use of any hiv vaccine, * no use of hydroxyurea, * no use of systemic corticosteroids or other non-permitted medications,

Keywords: immunotherapeutic injection
the effect of flexible thoracolumbar brace on idiopathic scoliosis, prospective, randomized, open-label trial

Conditions: Scoliosis Idiopathic

Summary: the effect of flexible thoracolumbar brace on idiopathic scoliosis, prospective, randomized, open-label trial


Eligibility criteria:
inclusion criteria: * who have idiopathic scoliosis, showing at cobb's angle over 20 degrees,less than 45 on x-ray exclusion criteria: * patients who underwent spinal surgery * patients with spinal scoliosis due to cerebral palsy, muscle paralysis, polio, congenital spinal abnormalities * patients observed with cobb's angle less than 20 degrees, over 45 degrees * patients complaining of acute low back pain * patients with cognitive impairment, severe mental illness, and inability to communicate
effect of arc1779 on cerebral microembolism in patients undergoing carotid endarterectomy

Conditions: Intracranial Embolism; Cerebral Thromboembolism; Carotid Stenosis

Summary: the purpose of this study is to determine, in patients undergoing carotid endarterectomy, the effect of arc1779 injection on the number of microembolic signals detected by transcranial doppler immediately after surgery. this study will also evaluate the safety of arc1779 injection with respect to bleeding risk in patients in the peri-operative (during surgery) period.


Eligibility criteria:
inclusion criteria: * male or female patients; * \>/= 18 to \</= 80 years of age; * carotid stenosis (either symptomatic or asymptomatic); * planned carotid endarterectomy; * female patients must be non-pregnant and willing to use effective, redundant methods of contraception (i.e., for both self and male partner) throughout the study and for at least 30 days after discontinuation of study drug treatment; * male patients must agree to use a medically acceptable contraceptive (abstinence or use of a condom with spermicide) throughout the study and for at least 30 days after discontinuation of study drug treatment; * all patients must be capable of understanding and complying with the protocol and must have signed the informed consent document. exclusion criteria: * lack of acoustic window allowing tcd recordings; * unable or unwilling to consent; * metallic prosthetic cardiac valve; * recent (\ 1/3 of the mca territory; * any history of hemorrhagic stroke; * thrombocytopenia; * coagulopathy; * trauma or surgery within preceding 30 days; * history of bleeding disorder, gastrointestinal ulcers, or other medical problem associated with an increased risk of bleeding; * use of warfarin and any chronic antithrombotic therapy other than acetylsalicylic acid and/or dipyridamole; patients previously treated with warfarin are eligible if the drug has been discontinued and the inr prior to randomization has returned to \<1.3; * use of clopidogrel, unless it has been discontinued at least 5 days prior to randomization; * fibrinolytic or gpiib/iiia inhibitor treatment within the preceding 24 hours.

Keywords: carotid endarterectomy von willebrand factor microembolic signal
mucosal immunity: influence on infectious viral load: a prospective observational study

Conditions: SARS-CoV-2 Infection; Influenza Viral Infections; Virus Shedding; Mucosal Immunity; RSV Infection

Summary: the goal of this observational study is to learn about the influence of pre-existing mucosal immunity, i.e. antibodies and immune cells that are present at the nasal mucosa before infection, on the infectious viral load after infection with sars-cov-2, influenza virus and rsv. the investigators will include app. 320 participants which will be followed for up to 17 months. during this time, the investigators will monitor their nasal mucosal antibodies at regular intervals and compare them to their infectious viral load if they are infected with sars-cov-2, influenza virus or rsv. participants are invited to take a test for sars-cov-2, influenza virus or rsv in case of respiratory symptoms. if participants are positive the investigators will follow their viral load kinetics by taking nasopharyngeal swabs every 2-3 days. the investigators will also record the duration and strength of the following symptoms: * cough * fever * tired * sore throat * difficulty breathing * respiratory distress * headache * loss (or alteration) of smell * loss (or alteration) of sense of taste * myalgias * chills * subjective fever * pink sputum (or coughing up blood) * thoracic pain * runny nose * abdominal pain * nausea * vomiting * diarrhea * constipation * irritated or watery eyes * rashes * other


Eligibility criteria:
inclusion criteria: * in general good health, as determined by study investigators * all participants must be living in the canton of geneva or working/studying in the canton of geneva and living in neighboring communities that are within one hour travelling distance by car. exclusion criteria: * inability to provide written consent. * severely immunocompromised subjects as determined by the study investigator * treated with inhaled drugs by nasal route within the last month
fungal infection on a joint prosthesis

Conditions: Fongal Infection

Summary: it is generally accepted that the fungal infection on a joint prosthesis is to be treated in two surgical time: implant removal and prosthetic reconstruction. the service took the option for over 10 years to treat bacterial infections in joint replacement by a change in time. in four recent cases the diagnosis initially suspected of bacterial infection has been restated on intraoperative bacteriological examinations fungal infection. it is therefore a potentially harmful side effect of the chosen treatment option, but 4 patients in question were all cured of their fungal infection after a postoperative antifungal therapy. the objective of this study is to report these cases for discussion on the therapeutic choices in fungal infections on joint replacement.


Eligibility criteria:
inclusion criteria: * patients over 18 years * patient having surgery for the management of fungal infection after change in one step in joint replacement prothesis in the participating services in 2014. exclusion criteria: * patients under 18 years

Keywords: fongal infection joint prosthesis prosthetic reconstruction
treatment of erectile dysfunction - long term safety and efficacy

Conditions: Erectile Dysfunction

Summary: open-label phase 3 study to evaluate the long-term safety and efficacy of udenafil, an orally administered selective inhibitor of pde-5 for the treatment of subjects with erectile dysfunction (ed).

patients completing the double-blind phase will be entered into study 01409 at the intermediate dose. up and down dose adjustments will be allowed.

Eligibility criteria:
inclusion criteria: * subject has completed study pr-01209 or pr-01309 * continues in a stable monogamous relationship with a consenting female partner who is at least 19 years of age. * partner is not pregnant or lactating exclusion criteria: * symptomatic coronary artery disease, myocardial infarction or cardiac surgical procedure. * cardiac arrhythmias requiring antiarrhythmic treatment * symptomatic congestive heart failure * taking nitrate medication in any form * uncontrolled diabetes (hba1c ≥ 13%) * hypersensitivity to phosphodiesterase type 5 (pde-5) inhibitors
prediction of weight gain by children and adolescents

Conditions: Overweight; Obesity

Summary: the 'meir children's sport and health center' runs a multi-disciplinary intervention program for the treatment of overweight and obese children and adolescents. the program includes physical activity, dietary guidelines, medical supervision and behavioral treatment. the participants are routinely weighed once a week, at the same day and time, in order to supervise their progress. according to our experience, the child can predict his weight change, based on his "behavior" in the previous week. to our knowledge the overweight/obese child's ability to predict his weekly weight change, while participating in a multi-disciplinary intervention program, has never been tested.

the aim of this study is to examine whether a child participating in a multi-disciplinary intervention program for treatment of the overweight and obese in meir medical center, can predict his weight change during intervention before the actual weighing. this study will include 1000 weight measurements of children and adolescents, boys and girls, ages 5-18 years. a patient might be measured several times. the data will be collected during 6 mounts. in this period the program participants will be asked, discretely, before being weighed if, in there opinion, they had lost or gained weight in the past week, and how mach and why.

Eligibility criteria:
inclusion criteria: * overweight and obese children and adolescence * boys and girls * ages 5-18 * that taking pat in a multi-disciplinary intervention program for treatment of the overweight and obese in meir medical center

Keywords: overweight obese children weighing weight
evaluation of the condition of rheumatoid arthritis after treatment

Conditions: Rheumatoid Arthritis

Summary: to examine the safety and effectiveness after xeljanz treatment in rheumatoid arthritis patients


Eligibility criteria:
inclusion criteria: * rheumatoid arthritis exclusion criteria: * other connective tissue disease
digital glucose monitoring in gestational diabetes

Conditions: Gestational Diabetes

Summary: assessing blood glucose control in women with gestational diabetes can be challenging. the standard of care remains visual inspection of blood glucose paper diaries of self-performed capillary monitoring during regular meeting in high risk pregnancy clinics. the researchers are interested in preforming a randomized control trial comparing women with the diagnosis of gestational diabetes with regular high-risk clinic surveillance to digital monitoring using an application in a smart-phone and submitting those values via email in addition to the regular clinic appointments. the primary outcome of the trial is to assess the compliance of the research group as compared to the control group.


Eligibility criteria:
inclusion criteria: * gestational diabetes exclusion criteria: * pre-gestational diabetes